Novavax | NVAX - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Adma Biologics USD 390.32M 86.99M 2026-03
Agenus USD -221.22M 49.89M 2026-03
AstraZeneca USD 50.3B 2.96B 2026-06
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Cassava Sciences USD 68.14M 6.26M 2026-03
Geron USD 229.11M 3.24M 2026-03
GlaxoSmithKline GBP 17.64B 223M 2026-06
MannKind USD -59.2M 8.17M 2026-03
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Moderna USD 6.76B 647M 2026-06
Novartis USD 38.93B 7.2B 2026-03
Novavax USD -144.76M 17.01M 2026-03
Pfizer USD 85.19B 4.91B 2026-06
Sanofi EUR 69.57B 3.24B 2026-06
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
TG Therapeutics USD 583.13M 64.89M 2026-03